Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Brookfield Infrastructure Partners LP (BIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Brookfield Infrastructure Partners LP — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.52 (market cap $5.07B), while Brookfield Infrastructure Partners LP trades at $39 (market cap $18.10B). The key difference: Brookfield Infrastructure Partners LP is far larger — about 3.6× ACADIA Pharmaceuticals Inc.'s market cap, and Brookfield Infrastructure Partners LP pays a 4.62% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | BIP | |
|---|---|---|
Market Cap | $5.07B | $18.10B |
Sector | Health | Industrials |
52-Week High | $29.41 | $42.62 |
52-Week Low | $20.06 | $29.81 |
Enterprise Value | $4.19B | $77.05B |
Dividend Yield | — | 4.62% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Brookfield Infrastructure Partners LP
Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.
Read more on BIP →
